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INTRODUCTION
Crohn’s disease (CD) progression is marked by the
occurrence of stricturing complications or intestinal
and perianal penetrating complications, typically
requiring surgery.
1 2 We previously reported three
factors at the time of diagnosis that increased the
chance of disabling disease during the 5 years
following: (1) age <40 years old, (2) presence of
perianal lesions and (3) the requirement for steroids
to control the ﬁrst ﬂare.
3 However, as the median
age of diagnosis is 27 years, the course of CD may
last more than 50 years in the Western world,
where the life expectancy of patients exceeds
70 years. Therefore, identifying predictive criteria
throughout such a long period remains challenging.
We believe the assessment of CD severity should
not be skewed by only taking into account occa-
sional disease events.
4 For example, one patient
may be operated on once and then experience
a long period of quiescent disease. CD manifesta-
tions are often quite active during the early few
years before subsequently resolving and becoming
more stable.
5 One may consider a CD complication
as an acute phenomenon without recurrence,
6 and,
in the absence of signiﬁcant sequelae, such an event
should therefore not be regarded as a marker of
severe disease. Notably, most therapeutic strategies
aim to avoid short-term complications; however,
CD is a chronic disease requiring lifelong moni-
toring. Very little is known about the long-term
evolution of CD. Therefore, the aim of our study
was to identify predictable factors associated with
a mild-to-moderate, long-term CD course; for this
purpose, we prospectively analysed a large cohort
of patients with CD over 15-year period.
METHODS
Patients
Patients with complete 15-year follow-up records
were selected from the MICISTA Registry. This
tertiary clinical database of more than 7000 patients
withinﬂammatoryboweldisease(IBD)evaluatedby
the same staff of doctors at Rothschild hospital
(1974 to 2002), then St-Antoine hospital (from 2003
through the present) in Paris (built in 1994). Data
werecollectedprospectively.CDdiagnosiswasbased
on the criteria deﬁned by Lennard-Jones.
7 In March
2010 there were 4306 patients with a ﬁnal diagnosis
of CD in the registry. Among this population, 600
patients with CD were seen in our unit during 1995
and were followed through to December 2009, or
death.Theyrepresent67%ofthetotalnumber(899)
of patients with CD seen in our unit at that time.
Characteristics of the CD cohort at entry (1995)
Characteristics of patients were recorded in the
MICISTA registry according to the medical charts
before 1994 and prospectively from 1995 onwards.
Disease location was assessed prior to inclusion in
the study by the most recent small bowel images
(x-ray) and endoscopic features. The extent of
previous intestinal resections in each individual was
codiﬁed using the Post-Surgical Handicap Index.
The Post-Surgical Handicap Index has been devel-
oped to predict the functional consequences of
intestinal resection for CD.
8 It is calculated from
operative records, taking into account the location
and extent of intestinal resection. An index score
equal or superior to 20 has a high predictive value of
diarrhoea following intestinal resection.
Description of the CD evolution 1995 to 2009
Disease activity was codiﬁed prospectively at each
visit or hospitalisation for every calendar year
according to a pre-established gradation from 0 to 5
(table 1). Disease activity was recorded during
hospitalisation only when symptoms were clearly
related to active CD and not treatment-related
complications. Similarly, only intestinal surgery or
proctological procedures performed for CD were
taken into account and codiﬁed in the hospital-
isation group. In addition, restorative procedures
performed in a patient with inactive disease were
not included in the grading. Finally, a stoma was
considered permanent if associated to a proctec-
tomy or still in place in 2009 after 5 years
(consecutively).
Classiﬁcation of the severity of the 15-year CD
course
In the absence of a well established classiﬁcation
system, a panel of 20 IBD experts from the ‘Groupe
d’Etudes Thérapeutiques des Affections Inﬂamma-
toires du tube Digestif’ (GETAID) was interviewed
to establish the most relevant criteria for discrimi-
nating a severe from a mild-to-moderate CD course
during a 15-year period. The proposed criteria were
the following: (1) number of years with active
disease, (2) chronic, disabling extraintestinal mani-
festations, (3) number of intestinal surgeries, (4)
disabling perianal disease, (5) number of perianal
surgical procedures, (6) requirement for a tempo-
rary or permanent stoma and (7) death related, or
not, to CD. Each expert codiﬁed items indepen-
dently. A consensus emerged for classifying the
evolution of CD as severe if during the 1995 to 2009
period one of the following criteria was met: (a)
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Inﬂammatory bowel diseaseactive disease (ie, grade >1), for more than 3 years consecutively
or not; (b) more than one intestinal surgery; (c) establishment of
a permanent stoma; (d) death related to CD or complications of
CD, or complications of CD treatment. The evolution was
considered as mild-to-moderate in all other cases.
Treatment
Disease ﬂares were treated with mesalamine (3e4 g daily) or
steroids (prednisolone 1 mg/kg per day, or budesonide 9 mg per
day, each progressively tapered after 4 weeks), according to their
clinical severity. When steroid treatment failed or was contra-
indicated, patients seen before 1999 were given enteral or
parenteral nutrition; those seen after June 1999 received Inﬂix-
imab. Adalimumab was used as a second-line anti-tumour
necrosis factor (TNF) treatment after 2006. Metronidazole or
ciproﬂoxacine were used in symptomatic perianal disease.
Patients with asymptomatic or moderately active forms of the
disease were treated with aminosalicylates (1.6e3 g daily).
Immunosuppressive drugs were used in patients that were
steroid dependent or poorly responsive to steroids. Azathioprine
(2 mg/kg per day) was preferentially used as the immunosup-
pressive drug, and increased to 2.5e3 mg/kg per day if needed.
Intramuscular methotrexate (15e25 mg, weekly) was used in
patients unresponsive or intolerant to azathioprine. In cases of
controlled CD, methotrexate was tapered after 3e6 months to
10e15 mg, weekly. In cases of poor responses to classical
immunosuppressants, anti-TNF therapies were used for
maintenance.
Although the overall strategy remained mostly unchanged,
there was a distinct tendency to initiate immunosuppressants
earlier in the disease course.
9 Surgery was performed for stenotic
complications, extraparietal complications, or intractable forms
of CD after well conducted medical management.
The maximum treatment received by one patient during each
calendar year was codiﬁed prospectively at each visit/hospital-
isation, according to a pre-established gradation (0e5 (table 1)).
All treatment(s) were taken into account, even in cases of short
duration.
Statistical analysis
Statistical comparisons were performed using c
2, Fisher’s exact,
Student t test or Wilcoxon test where appropriate. Identiﬁcation
of factors associated with mild-to-moderate, 15-year CD course
was determined by using univariate and multivariate analyses.
Most covariates were collected in 1995: age, gender, family
history, educational level, obesity, disease duration, disease
location according to Montreal classiﬁcation (ie, at ﬁrst surgery
or in 1995 in patients who had not be operated upon), rectal
involvement, perianal disease, systemic manifestations, prior
intestinal stricture (Montreal classiﬁcation), prior intestinal
perforation (Montreal classiﬁcation), prior perianal ﬁstula, prior
intestinal resection, prior immunosuppressive treatment and
current immunosuppressive treatment. Three variables were
collected at the end of the follow-up: (1) quality of follow-up
care (how many visits per year), (2) any use of oral contracep-
tives during their lifetime and (3) active smoking during the
15-year study. The smoking variable was qualiﬁed by more than
one cigarette per day for at least 1 year. Statistically signiﬁcant
covariates (a¼5%) in univariate analyses were included in
a stepwise logistic regression (entering effect ¼0.10, removing
¼0.05). The goodness of ﬁt for the ﬁnal multivariate model was
assessed with the Hosmer and Lemeshow test. The power of the
model’s predicted values to discriminate between severe and
mild-to-moderate cases was quantiﬁed by the area under the
receiver operating characteristic (ROC) curve (AUC). Statistical
analyses were performed using SAS software V.9.1 (SAS, Cary,
North Carolina, USA).
RESULTS
Classiﬁcation of the severity of the 15-year disease course
The 15-year CD course was classiﬁed as mild-to-moderate in 279
of the 600 patients. Among them, all the patients experienced at
least 12 years with no active disease, except six patients who
died before 2010. Those six patients were classiﬁed as mild-to-
moderate because four of them died after a period of 9e10 years
of CD remission, and two of them died after only 1 year with
active disease during the 10e12 previous years. A total of 61
patients (22%) were operated on once during the 15-year period
for active or complicated CD. The other 321 patients were
classiﬁed in the severe CD group because of active disease for
more than 3 years (n¼286), at least two abdominal operations
for active or complicated CD (n¼58), the establishment of
permanent stoma (n¼42), or death related to CD (n¼23). Tables
2e4 give the clinical characteristics of the two groups in 1995, at
the end of follow-up and through the 15-year study, respectively.
Year-by-year disease activity
In the entire cohort of 600 patients, 6288 patient-years with
inactive disease existed (grade 0e1; 72.2%), 1641 patient-years
with ﬂare or chronic active disease not requiring hospitalisation
existed (grade 2 or 3; 18.8%), 453 patient-years with hospital-
isation without abdominal surgery existed (grade 4; 5.2%) and
344 patient-years with abdominal surgeryexisted (grade5; 3.9%).
Disease activity during the calendar years 1995 to 2009 in
mild-to-moderate and severe CD is indicated in ﬁgure 1A. A
signiﬁcant trend towards lower disease activity is observed
during the most recent years in severe and mild-to-moderate CD
groups. When taking into account the entire cohort, the
percentage of patients with active disease decreased linearly over
the years from 43% to 14% (p<0.001). In the mild-to-moderate
CD group, the proportion of patient-years with active disease
was 14.8%, 6.7% and 5.6% during the periods 1995 to 1999, 2000
to 2004 and 2005 to 2009, respectively (p<0.001). The propor-
tion of patient-years with active disease in the severe CD group
decreased from 60% (1995 to 1999) to 42% (2000 to 2004) and
32% (2005 to 2009) (p<0.001).
In mild-to-moderate CD the percentage of patients with
active disease each calendar year varied between 22.2% (1995)
and 2.9% (2007) (median, 9.3% in 2001). Hospitalisation and
Table 1 Prospective codiﬁcation of one individual in
a calendar year
Activity and treatment N
Disease activity
Quiescent (no symptoms) 0
Minor symptoms without ﬂare 1
Mild symptoms 2
Flare-up or chronic active disease 3
CD-related hospitalisation 4
Abdominal surgery for active CD or complication 5
Maximal treatment received during the year
No treatment for CD 0
5-amino-salicylates or antibiotics for CD 1
Low dose steroids (<10 mg Prednisone per day) 2
Steroids 3
Immunosuppressants 4
Anti-TNF agents 5
CD, Crohn’s disease; TNF, tumour necrosis factor.
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Inﬂammatory bowel diseasesurgery were required in few patients, and these events almost
exclusively occurred during the early years of the study (1995 to
1999) (ﬁgure 1A). In severe CD the percentage of patients with
active disease each calendar year varied between 67% (1995) and
25.1% (2007) (median, 43.2% in 2002). The annual rate of
hospitalisation, excluding abdominal surgery, varied from 13.4%
(1996) to 2.7% (2007) (median, 7.3% in 2002) and the annual
rate of abdominal surgery varied from 10.6% (1998) to 2% (2007)
(median, 5.5% in 2000) (ﬁgure 1A).
Medical therapeutic requirements
The number of patients with CD in the mild-to-moderate and
severe groups who received 5-aminosalicylic acid (5-ASA),
steroids, immunosuppressants and anti-TNF treatment as
maximal treatment are indicated for each calendar year in ﬁgure
1B. In both groups a gradual increase in the use of immuno-
suppressants and anti-TNF treatment is observed over time. The
proportion of patient-years in which immunosuppressants and/
or anti-TNF treatment were used in mild-to-moderate CD
increased from 23.2% (1995 to 1999) to 26.4% (2000 to 2004)
and ﬁnally to 27.8% (2005 to 2009) (p<0.001). In severe CD,
these ﬁgures were 41.2%, 56.2% and 62.1%, respectively
Table 3 Characteristics of the mild-to-moderate and severe Crohn’s
disease (CD) groups at the end of follow-up
Mild-to-moderate
15-year CD
Severe
15-year CD p Value
N 279 321
Deceased, % 6 (2) 29 (9) NA
Age 49 (42e59) 45 (38e52) <0.0001
Post-Surgical Handicap Index 19 (0e30) 20 (0e37) 0.016
Permanent stoma, % 23 (8) 53 (17) 0.002
All quantitative data are given as median (IQR).
NA, not applicable (item linked to the post hoc classiﬁcation).
Table 2 Characteristics of patients in the mild-to-moderate and severe Crohn’s disease (CD) groups in
1995
All
Mild-to-moderate
15-year CD Severe 15-year CD p Value*
N 600 279 321
Age, years 32.6 (26e42) 36 (28e46) 31 (24e39) <0.0001
Female, % 356 (59) 158 (57) 198 (62) NS
Disease duration, years 5.9 (2.3e10.0) 9.4 (3.9e15.2) 5.4 (2.1e10.3) <0.0001
IBD family history, % 144 (24) 67 (24) 77 (24) NS
Extradigestive manifestations, % 259 (43) 113 (40) 146 (45) NS
Disease location, %
L1 219 (36) 107 (38) 112 (35)
L2 171 (28) 71 (25) 100 (31) NS
L3 209 (35) 100 (36) 109 (34)
Upper tract involvement (L4), % 62 (10) 28 (10) 53 (17) 0.02
Rectal involvement, % 229 (38) 90 (32) 139 (43) 0.006
Perianal lesions, % 258 (43) 122 (44) 136 (42) NS
Disease behaviour, %
B1 376 (63) 152 (54) 224 (70) 0.0001
B2 82 (14) 46 (16) 36 (11)
B3 143 (24) 81 (29) 61 (19)
Prior immunosuppressants, % 166 (28) 65 (23) 101 (31) <0.0001
Prior intestinal resection, % 265 (44) 152 (54) 113 (35) <0.0001
Permanent stoma, % 34 (6) 23 (8) 11 (3) 0.01
Post-Surgical Handicap Index 20 (0e34) 9 (0e25) 0 (0e18) <0.0001
Obesity, % 115 (19) 57 (20) 58 (18) NS
High educational level, % 235 (39) 126 (45) 109 (34) 0.005
All quantitative data are given as median (IQR).
*Comparisons between mild-to-moderate and severe 15-year CD groups.
IBD, inﬂammatory bowel disease; NS, not signiﬁcant.
Table 4 Main events during the 15-year follow-up
Mild-to-moderate
15-year CD
Severe
15-year CD p Value
N 279 321
Close follow-up, % 187 (67) 208 (65) NS
Ever use of oral contraceptives, % 54 (49)* 82 (61)* NS
Any smoking, % 121 (43) 182 (57) 0.001
Death related to CD, % 0 23 (7) NA
Death unrelated to CD, % 6 (2) 6 (2) NS
Intestinal adenocarcinoma, % 1 18 <0.0001
Lymphoma, % 1 1 NS
Other malignancies, % 20 14 NS
No. of years with active disease
0 89 (32) 4 (1) NA
1 62 (22) 6 (2)
2 69 (25) 11 (3)
3 59 (21) 17 (5)
4e5 0 108 (34)
6e10 0 134 (42)
>10 0 41 (13)
Changing behaviour, %
B1 to B2 19 (12)* 41 (18)* <0.001
B1 to B3 18 (12)* 56 (25)* e
B2 to B3 3 (7)* 4 (11)* NS
Intestinal resection(s) 61 (22) 189 (59) NA
Delta PSHI 0 (0e0) 7 (0e21) <0.01
Establishment of a permanent stoma 0 42 (14)* NA
Proctological procedure(s) 20 (8)* 75 (24)* <0.0001
All quantitative data are given as median (IQR).
*Per cent calculated in women of child-bearing age.
CD, Crohn’s disease; NA, not applicable (item linked to the post hoc classiﬁcation); NS, not
signiﬁcant percentage calculated in the appropriate subgroup of patients; PSHI, Post-
Surgical Handicap Index.
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Inﬂammatory bowel disease(p<0.001). Trends in both groups exhibited a coincident decrease
in 5-ASA and steroid usage as the maximal treatment over time.
As the use of 5-ASA and steroids in association with immuno-
suppressants was not reported, the observed decrease in the
proportion of patients taking 5-ASA or steroids cannot be
interpreted. Finally, there was a signiﬁcant increase in the
percentage of patients receiving no medical treatment over time,
notably in the most recent years. This trend was more marked in
the mild-to-moderate CD group (from 25.9% in 1995 to 1999 to
43% in 2005 to 2009, p<0.001) than in severe CD (from 10.2% in
1995 to 1999 to 19.9% in 2005 to 2009, p<0.001).
In total, throughout the 15-year period, 116 patients with
mild-to-moderate CD (41.6%) eventually received immunosup-
pressants and 14 received anti-TNF treatment (5%). In the
severe CD cohort, 268 (83.5%) patients received immunosup-
pressants and 97 (31.4%), received anti-TNF treatment.
Factors associated with a mild-to-moderate disease course
Table 5 indicates the variables selected by univariate analysis
which entered the multivariate model. After adjustment for
confounding, signiﬁcant factors associated with a mild-to-
moderate 15-year disease course were the following: (1) non-
smoking, (2) higher educational level, (3) rectal sparing, (4) older
age and (5) longer disease duration prior to inclusion. The model
was a good ﬁt to the data (Hosmer and Lemeshow: p¼0.51). The
area under the ROC curve was 0.69. The probability of a mild-
to-moderate course was given by the following formula:
logit(p) ¼ 0.8715+0.01483age (years)+0.04793disease dura-
tion (years) 0.39923ever smoking (0 or 1) 0.45033rectal
involvement (0 or 1)+0.39153high educational level (0 or 1).
This model demonstrates that a 15-year time course increased
the probability of having subsequent mild-to-moderate disease
by 0.20860.032. This increased probability was similar when
Figure 1 Year-by-year disease activity and
maximal treatment from 1995 to 2009 in the
two groups of patients with Crohn’s disease
(CD). (A) Year-by-year disease activity from
1995 to 2009. (B) Year-by-year maximal
treatment from 1995 to 2009 in the two
groups of patients with CD.
Table 5 Variables associated with a mild-to-moderate Crohn’s disease (CD) 15-year course selected by
logistic regression
Univariate analysis Multivariate analysis
p Value OR (CI 95%) p Value OR (CI 95%)
Age <0.0001 1.03 (1.02 to 1.04) 0.041 1.01 (1.00 to 1.03)
High educational level 0.005 1.60 (1.15 to 2.23) 0.026 1.48 (1.05 to 2.09)
Ever smoking 0.001 0.58 (0.42 to 0.81) 0.022 0.67 (0.48 to 0.94)
Disease duration <0.0001 1.06 (1.04 to 1.09) <0.001 1.05 (1.02 to 1.08)
Rectal involvement 0.006 0.62 (0.45 to 0.87) 0.011 0.64 (0.45 to 0.90)
Prior intestinal stricture <0.001 2.09 (1.39 to 3.14) NS
Prior intestinal perforation 0.002 1.86 (1.26 to 2.72) NS
Prior intestinal resection <0.0001 2.20 (1.59 to 3.06) NS
NS, not signiﬁcant.
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Inﬂammatory bowel diseaseanalysing patients with mild-to-moderate (0.20160.039) and
severe disease courses (0.21460.024).
Table 6 indicates the respective contribution of each selected
variable to the different criteria used for deﬁning CD severity.
Neither CD-related death nor the surgical criteria (more than
one abdominal surgery) were signiﬁcantly associated with any
selected variable. However CD activity was associated with the
ﬁve selected variables, and the establishment of a permanent
stoma was associated with rectal involvement and lower
educational level.
DISCUSSION
The present study shows that long-term prognosis of CD is not
related to anatomical characteristics of the disease, except for
rectal involvement. Smoking and low educational level are
associated with a more severe disease course. In addition, this
study demonstrates that age and disease duration are associated
with a less severe course.
To date, our study is unique in the literature with regard to
the number of patients, the prospective collection of data and
the management of the study by a small, consistent group of
doctors. Compared to population-based studies, referral-based
cohorts, such as our cohort, enrol younger patients with more
ﬁstulas, steroids and immunosuppressant use.
10 This recruit-
ment bias may lead to an overestimation of patients with severe
disease but does not compromise the comparisons drawn
between severe and mild-to-moderate CD. Thus, the proposed
prognostic factors should be validated in independent popula-
tion-based cohorts.
Disease location and behaviour had no impact on the overall
severity of CD course throughout the 15-year study. It is well
established that the risk of intestinal surgery in CD is increased
in cases of previous intestinal complications,
6 11 12 especially
when the small bowel is involved.
13 14 However the risk of
surgery should not be regarded as a major issue when the overall
prognosis is discerned. Different from colitis, ileal CD is char-
acterised by a higher need for surgery, balanced by a lesser
inﬂammatory activity, thus it is not surprising that the long-
term prognosis is not different in these two conditions. The
behaviour of our patients was classiﬁed according to the
Montreal classiﬁcation, which is based upon the cumulative
complications rate.
15 The absence of an effect on the cumulative
behaviour at a given time on the subsequent evolution conﬁrms
its limited prognostic value.
12Moreover, we did not observe
that patients with perianal disease experience a more severe CD
course.
16 Our study highlighted rectal involvement has an effect
on long-term prognosis and that this effect may be due to the
association between rectal involvement and refractory perianal
disease with the need for proctectomy (table 6). This result is in
accordance with most data showing that rectal involvement is
associated with a higher risk for permanent stomas in patients
requiring surgery for perianal lesions.
17 18
Thelong-termharmfuleffectofsmokinginCDwasonceagain
conﬁrmed in our cohort. Of note, smoking was associated with
increased disease activity but not with a need for a second oper-
ation (table 6).
19 20 The beneﬁcial effect of a higher educational
level was somewhat unexpected, particularly because, in France,
level of education has no impact on access to health resources.
21
However, educational level may inadvertently affect compli-
ance
22 and, indeed, non-adherence has been reported in over one-
third of patients taking maintenance therapies for inﬂammatory
bowel disease which may negatively contribute to CD manage-
ment.
23 24 Better compliance may be achieved in patients with
CDwithalowereducational levelthroughenrolmentinapatient
association.
21 25 Furthermore, a high educational level may be
linked to a more cautious lifestyle behaviour and somehow
protect patients with CD from environmental triggers.
Disease duration and age at inclusion in the study were both
independent factors associated with a lesser severity of CD. The
beneﬁcial effect of time was not related to prior intestinal resec-
tion (table 5). We calculated from the logistic regression model
that a 15-year lag time decreased the probability of having
a subsequent severe course by approximately 20%. To our
knowledge this is the ﬁrst study demonstrating that, time is an
independent factor for lower CD disease activity. The IBSEN
study
12 demonstrated a greater likelihood of prolonged remission
was associated with patients over 40 years of age. However, the
landmark study by Munkholm et al
5 showed that the initial
3 years following diagnosis are the most active and should be
considered separately for these analyses. In the latter study,
a remarkably constant percentage of patients (55%) were classi-
ﬁed in clinical remission each year after the initial 3 years after
diagnosis.
5 However, more than 15 years after diagnosis, there
was a higher proportion of patients changing from active to
remission status than vice versa each year.
5 In addition, our study
shows, through year-by-year analysis of CD activity, the positive
effect of disease duration and was more marked during the more
recent years (ﬁgure 1A). When analysing our cohort excluding
patients with <3 years of disease evolution before entering the
cohort (n¼159), we found similar results (data not shown). In
mild-to-moderate CD, percentage of patients with active disease
decreased over the years and a large cohort of patients was
Table 6 Association of the selected variables with the criteria deﬁning 15-year Crohn’s disease (CD) severity
Age <33 years*
Lower educational
level Ever smoking
Rectal
involvement
CD duration
<7 years*
N 300 365 303 229 300
Activity >3 years 172 (57) 0.001 190 (52) 0.01 171 (56) 0.001 122 (53) 0.03 172 (57) 0.001
114 (38) 96 (41) 115 (39) 164 (44) 114 (38)
>1 bowel surgery 35 (12) NS 37 (10) NS 31 (10) NS 22 (10) NS 34 (11) NS
23 (8) 21 (9) 27 (9) 36 (10) 24 (8)
Permanent stomay 21 (7) NS 32 (9) 0.04 22 (8) NS 30 (15) 0.001 20 (7) NS
21 (8) 10 (5) 20 (7) 12 (3) 22 (8)
CD-related death 3 (1) 0.003 13 (4) NS 9 (3) NS 10 (4) NS 8 (3) NS
20 (7) 10 (4) 14 (5) 13 (4) 15 (5)
Any criteria 182 (61) 0.001 212 (58) 0.005 182 (60) 0.001 139 (61) 0.005 187 (62) 0.001
139 (46) 109 (46) 139 (47) 182 (49) 134 (45)
*Median value for the 600 patients.
yPatients with prior permanent stoma excluded.
NS, not signiﬁcant.
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currently followed. Similarly, in severe CD cases, there was also
a higher proportion of patients without any treatment. The
proportion of patients under immunosuppressants (comprising
steroids and anti-TNF) did not change over years. Thus, it is
probable that the decrease in disease activity observed over the
years in the study was poorly related to the treatment regimen,
but was the consequence of a natural waning of disease. Taken
together these data support the conclusion that overall CD
activity declines over time, albeit in a limited magnitude.
Finally, long-term evolution of CD is weakly predictable. New
approaches using biomarkers to predict disease course are
needed.
26 27 Moreover, about one-half of the patients from
a referral centre will have a mild-to-moderate, long-term
evolution and this proportion should be kept in mind when
considering treatment strategies. In addition, among factors
associated with a severe evolution of CD, smoking remains the
most challenging factor for patients to overcome. Lastly, rectal
disease should receive major attention in order to decrease
permanent stoma, and, moreover, efforts should be attempted to
better understand CD progression.
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Correction
Welsch C, Jesudian A, Zeuzem S, et al. New direct-acting antiviral agents for the treatment
of hepatitis C virus infection and perspectives. Gut 2012;61(Suppl 1):i36ei46. doi:10.1136/
gutjnl-2012-302144.
The term “pegylated interferon-N1 plus ribavirin” in the abstract should read “pegylated
interferon-a plus ribavirin”.
Gut 2012:61:1145. doi:10.1136/gutjnl-2012-302144corr1
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